{"corpus_id":207602966,"paper_sha":"65e50d3552403a73b14b0d6e701fe036dfa0d8fc","doi":"10.3748/wjg.v21.i3.829","arxiv_id":null,"pmid":25624716,"pmcid":"PMC4299335","mag_id":2347187968,"dblp_id":null,"acl_id":null,"title":"Recent advances in prevention of hepatitis B recurrence after liver transplantation.","year":2015,"publication_date":"2015-01-21","venue":"World Journal of Gastroenterology","journal":{"name":"World journal of gastroenterology","pages":"\n          829-35\n        ","volume":"21 3"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't","Review"],"s2_fields_of_study":["Medicine"],"reference_count":65,"citation_count":13,"influential_citation_count":1,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antiviral Agents","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000998"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"End Stage Liver Disease","mj":false,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"surgery","mj":true,"ui":"Q000601"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D058625"},{"d":"Hepatitis B","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"},{"q":"diagnosis","mj":false,"ui":"Q000175"},{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D006509"},{"d":"Hepatitis B virus","mj":false,"qs":[{"q":"drug effects","mj":true,"ui":"Q000187"},{"q":"pathogenicity","mj":false,"ui":"Q000472"}],"ui":"D006515"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Immunoglobulins","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"}],"ui":"D007136"},{"d":"Liver Transplantation","mj":false,"qs":[{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D016031"},{"d":"Recurrence","mj":false,"ui":"D012008"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Virus Activation","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D014775"}],"chemicals":[{"n":"Antiviral Agents","ui":"D000998","reg":"0"},{"n":"Immunoglobulins","ui":"D007136","reg":"0"},{"n":"hepatitis B hyperimmune globulin","ui":"C045213","reg":"XII270YC6M"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Liver transplantation is the only effective treatment for hepatitis B virus (HBV)-related end-stage liver disease. However, without antiviral prophylaxis, the recurrence rate of hepatitis B is as high as 80%-100%, which leads to a 50% mortality rate in the first 2 years after liver transplantation. Combination therapy of hepatitis B immunoglobulin (HBIG) and lamivudine demonstrated a higher efficacy of prophylaxis and further reduced the rate of recurrence to < 10%. The strategy of HBIG combined with lamivudine has been the standard treatment in many centers. However, the high rate of lamivudine resistance and the many disadvantages of HBIG have compelled surgeons to reconsider the long-term efficacy of this strategy for the prevention of HBV reinfection. Recently, new nucleos(t)ide analogues, such as entecavir and tenofovir, have been approved as first-line monotherapies for the treatment of chronic hepatitis B infection. These antiviral medicines have replaced lamivudine as the first choice in the prevention of HBV recurrence after liver transplantation. Various therapies that are composed of entecavir, tenofovir, and lamivudine plus adefovir, with or without HBIG have been adopted in several liver transplant centers. This article reviews the recent advances in prophylaxis for the recurrence of hepatitis B after liver transplantation.","claims":[{"public_id":"cl_9e20d34c050fe0f18e46df4846ae4d36","status":"active","text":"Entecavir and tenofovir have replaced lamivudine as the first choice for preventing hepatitis B recurrence after liver transplantation.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9e20d34c050fe0f18e46df4846ae4d36"},{"public_id":"cl_620592d0337eb0ef8a4ceb707e5373dd","status":"active","text":"HBIG combined with lamivudine reduced hepatitis B recurrence after liver transplantation to below 10%.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_620592d0337eb0ef8a4ceb707e5373dd"},{"public_id":"cl_8f851a7afbbd50e55d4a07e76b8a1f12","status":"active","text":"Multiple prophylactic regimens using entecavir, tenofovir, or lamivudine plus adefovir, with or without HBIG, are now adopted in several liver transplant centers.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8f851a7afbbd50e55d4a07e76b8a1f12"}],"concepts":[{"public_id":"co_033936adff8a4ebd81defaef93e31fc7","status":"active","name":"lamivudine","description":"An antiviral nucleoside analogue used against hepatitis B virus infection.","types":["antiviral drug","nucleos(t)ide analogue"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_033936adff8a4ebd81defaef93e31fc7"},{"public_id":"co_0fb12df302f2b8999e6f52c914063280","status":"active","name":"combination therapy of hepatitis B immunoglobulin and lamivudine","description":"A prophylactic regimen combining passive immunoglobulin with lamivudine.","types":["combination therapy","prophylactic regimen"],"aliases":["HBIG and lamivudine combination therapy"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0fb12df302f2b8999e6f52c914063280"},{"public_id":"co_344fc1ef26702d9cd8ad429c9c882cf4","status":"active","name":"liver transplantation","description":"A surgical procedure in which a diseased liver is replaced with a donor liver.","types":["surgical procedure"],"aliases":["liver transplant"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_344fc1ef26702d9cd8ad429c9c882cf4"},{"public_id":"co_3cf6ebc69cb3c32a9bb40d25c60c9332","status":"active","name":"tenofovir","description":"An antiviral nucleotide analogue used to treat chronic hepatitis B infection.","types":["antiviral drug","nucleos(t)ide analogue"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3cf6ebc69cb3c32a9bb40d25c60c9332"},{"public_id":"co_481584144058cc2c11a58772a7495438","status":"active","name":"hepatitis B immunoglobulin","description":"A hepatitis B-specific immunoglobulin used as passive immunoprophylaxis.","types":["prophylactic agent","immunoglobulin"],"aliases":["HBIG"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_481584144058cc2c11a58772a7495438"},{"public_id":"co_6ba70dcbdf39b3a88b0568df48aad741","status":"active","name":"lamivudine plus adefovir","description":"A combination antiviral regimen pairing lamivudine with adefovir.","types":["combination therapy","antiviral regimen"],"aliases":["lamivudine/adefovir"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6ba70dcbdf39b3a88b0568df48aad741"},{"public_id":"co_7664a285dc0bf7108119ffcb4a4d73c6","status":"active","name":"entecavir","description":"An antiviral nucleoside analogue used to treat chronic hepatitis B infection.","types":["antiviral drug","nucleos(t)ide analogue"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7664a285dc0bf7108119ffcb4a4d73c6"},{"public_id":"co_a12ec67d050f68c4592d73078d4888a1","status":"active","name":"hepatitis B recurrence after liver transplantation","description":"Return of hepatitis B infection following liver transplantation in recipients with hepatitis B virus-related disease.","types":["clinical outcome"],"aliases":["HBV recurrence after liver transplantation","HBV reinfection after liver transplantation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a12ec67d050f68c4592d73078d4888a1"},{"public_id":"co_acd2dd5b425104affc7cf8d7cc9ade84","status":"active","name":"antiviral prophylaxis","description":"Preventive antiviral treatment intended to stop hepatitis B recurrence after transplantation.","types":["preventive treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_acd2dd5b425104affc7cf8d7cc9ade84"},{"public_id":"co_e034989751cbb9935565a9b89440716c","status":"active","name":"adefovir","description":"An antiviral nucleotide analogue used in combination regimens for hepatitis B.","types":["antiviral drug","nucleos(t)ide analogue"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e034989751cbb9935565a9b89440716c"}],"external_ids":{"DOI":"10.3748/wjg.v21.i3.829","ArXiv":null,"PubMed":25624716,"PubMedCentral":"PMC4299335","MAG":2347187968,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/207602966","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634395,"paper_uid":"b9cffb03-c704-474b-b059-78e29c8a28f2","canonical_identity":{"paper_id":634395,"paper_uid":"b9cffb03-c704-474b-b059-78e29c8a28f2","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/207602966"}